This is the authors' abstract. We don't add key points for this paper.
The lack of precise, real-time analytical tools for monitoring tumor microenvironment changes during treatment hinders advancements in integrated diagnostic and therapeutic platforms. Traditional caspase-3 monitoring strategies are limited by their inability to address drug resistance and newly discovered apoptotic pathways, leading to reduced accuracy and practicality. To overcome these limitations, we developed a fluorescence-based "Trojan horse" nanosystem, PFpR@CM, featuring high-sensitivity Caspase-1 detection, tumor-targeted delivery, and photothermal therapy. Caspase-1 was selected as a biomarker due to its ability to provide accurate feedback on reactive oxygen species (ROS) generation. The system employs Fe-doped polydopamine nanoparticles and red fluorescent carbon quantum dots (RCQDs) as the analytical core, achieving a detection limit of 0.024 U/mL for Caspase-1 with a linear range of 0.05-1.0 U/mL. By integrating MG-63 cell membrane camouflage, PFpR@CM ensures tumor specificity and immune evasion, allowing precise in situ monitoring of ROS production during ferroptosis. Experimental results demonstrate that the system enables simultaneous real-time fluorescence tracking and localized therapeutic interventions, achieving over 80% tumor volume reduction in vivo with minimal systemic toxicity. This work establishes a novel analytical chemistry approach for multifunctional tumor monitoring and treatment, providing an innovative solution to challenges in precision oncology.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: